Elicio Gross Profit from 2010 to 2024

ELTX Stock

5.20 0.11 2.16%

Elicio Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Elicio Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-1.2 M

Current Value

-1.1 M

Quarterly Volatility

6.9 M

Credit Downgrade

Yuan Drop

Covid

Check Elicio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elicio Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 391.6 K, Depreciation And Amortization of 828.2 K or Selling General Administrative of 6.8 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 3.89. Elicio financial statements analysis is a perfect complement when working with Elicio Therapeutics Valuation or Volatility modules.

Check out the analysis of Elicio Therapeutics Correlation against competitors.

For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.

Latest Elicio Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Elicio Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Elicio Therapeutics minus its cost of goods sold. It is profit before Elicio Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Elicio Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Elicio Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Gross Profit

Timeline

Elicio Gross Profit Regression Statistics

	Arithmetic Mean	2,361,433
	Coefficient Of Variation	292.01
	Mean Deviation	3,295,542
	Median	1,062,000
	Standard Deviation	6,895,653
	Sample Variance	47.6T
	Range	28.2M
	R-Value	0.15
	Mean Square Error	50.1T
	R-Squared	0.02
	Significance	0.59
	Slope	231,652
	Total Sum of Squares	665.7T

Elicio Gross Profit History

	2024	-1.1 M
	2023	-1.2 M
	2022	-1.1 M
	2021	27.1 M

Other Fundumenentals of Elicio Therapeutics

Gross Profit Margin

Elicio Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Short Long Term Debt
Total Assets		0.08	-0.91	0.62	0.08	-0.92	0.97	0.44	0.18	0.09	0.93	0.79	0.07	0.13	0.79	0.83	-0.59
Total Stockholder Equity	0.08		0.03	-0.34	-0.49	-0.24	0.16	-0.11	-0.97	0.99	0.23	-0.38	0.42	-0.36	-0.38	0.3	-0.67
Net Tangible Assets	-0.91	0.03		-0.82	-0.42	0.96	-0.91	-0.14	-0.28	0.0	-0.74	-0.86	0.21	-0.3	-0.86	-0.88	0.65
Current Deferred Revenue	0.62	-0.34	-0.82		0.73	-0.7	0.64	-0.01	0.5	-0.26	0.46	0.86	-0.72	0.78	0.86	0.49	-0.31
Net Debt	0.08	-0.49	-0.42	0.73		-0.27	0.18	-0.6	0.51	-0.44	-0.2	0.39	-0.85	0.6	0.39	0.21	0.07
Retained Earnings	-0.92	-0.24	0.96	-0.7	-0.27		-0.95	-0.11	-0.01	-0.26	-0.8	-0.73	0.09	-0.2	-0.73	-0.94	0.79
Accounts Payable	0.97	0.16	-0.91	0.64	0.18	-0.95		0.25	0.09	0.18	0.87	0.71	-0.02	0.16	0.71	0.86	-0.61
Net Receivables	0.44	-0.11	-0.14	-0.01	-0.6	-0.11	0.25		0.22	-0.12	0.65	0.43	0.42	-0.01	0.43	-0.02	-0.01
Total Liab	0.18	-0.97	-0.28	0.5	0.51	-0.01	0.09	0.22		-0.96	0.01	0.59	-0.4	0.39	0.59	-0.07	0.49
Net Invested Capital	0.09	0.99	0.0	-0.26	-0.44	-0.26	0.18	-0.12	-0.96		0.25	-0.33	0.33	-0.26	-0.33	0.29	-0.69
Total Current Assets	0.93	0.23	-0.74	0.46	-0.2	-0.8	0.87	0.65	0.01	0.25		0.7	0.19	0.14	0.7	0.66	-0.59
Capital Stock	0.79	-0.38	-0.86	0.86	0.39	-0.73	0.71	0.43	0.59	-0.33	0.7		-0.34	0.54	1.0	0.55	-0.35
Net Working Capital	0.07	0.42	0.21	-0.72	-0.85	0.09	-0.02	0.42	-0.4	0.33	0.19	-0.34		-0.9	-0.34	0.12	-0.16
Short Term Debt	0.13	-0.36	-0.3	0.78	0.6	-0.2	0.16	-0.01	0.39	-0.26	0.14	0.54	-0.9		0.54	-0.11	0.05
Common Stock	0.79	-0.38	-0.86	0.86	0.39	-0.73	0.71	0.43	0.59	-0.33	0.7	1.0	-0.34	0.54		0.55	-0.35
Property Plant Equipment	0.83	0.3	-0.88	0.49	0.21	-0.94	0.86	-0.02	-0.07	0.29	0.66	0.55	0.12	-0.11	0.55		-0.8
Short Long Term Debt	-0.59	-0.67	0.65	-0.31	0.07	0.79	-0.61	-0.01	0.49	-0.69	-0.59	-0.35	-0.16	0.05	-0.35	-0.8

Click cells to compare fundamentals

About Elicio Therapeutics Financial Statements

Elicio Therapeutics investors use historical fundamental indicators, such as Elicio Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elicio Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-1.2 M	-1.1 M
Gross Profit Margin	0.86	0.46

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC